Filing Flows

Filing Flows › 8-K events › Harmony Biosciences Holdings

Harmony Biosciences Holdings: results of operations

Form 8-K filed Nov 4, 2026 · items 2.02, 7.01

FDA decisionsHarmony Biosciences Reports Q3 Financial Results

What the filing says

On Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile

ScaleThe filing names $1.00B: about 93% of Harmony Biosciences Holdings' annual revenue ($1.08B, four times the latest quarter).

Read the filing on SEC EDGAR →

What usually followsAcross 69,115 8-Ks reporting Item 2.02 (results of operations) in our universe, the stock's median move the next session was +0.2% (typical size ±3.6%, up 51% of the time); over the following 21 sessions, +1.2%. Every item ranked →

Harmony Biosciences Holdings at a glance

Latest quarterQ3 2026
Revenue$268.9M
Revenue Y/Y+12%
Operating margin20.2%
IndustryPharmaceutical Preparations

Harmony Biosciences Holdings, Q3 2026: revenue $269M (+12% year over year), operating margin 20.2%. The chart follows the revenue to costs, profit and cash.

Harmony Biosciences Holdings: every quarter, Q/Q and Y/Y, holders and guidance →

Harmony Biosciences Holdings’s other material 8-Ks

Other recent fda decisions

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.